13 July 2022 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of adults with active psoriatic arthritis.

Risankizumab, when used alone or in combination with methotrexate, is recommended as an option for the treatment of adults with active psoriatic arthritis whose disease has not responded well enough to disease-modifying anti-rheumatic drugs or who cannot tolerate them.

It is recommended only if they have:

• Peripheral arthritis with 3 or more tender joints and three or more swollen joints
• Moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index score greater than 10)
• Had two conventional DMARDs and at least one biological disease-modifying anti-rheumatic drug

Risankizumab is recommended only if AbbVie provides it according to the commercial arrangement.

Read NICE technology appraisal guidance